CONTENTS

• Rapid Reference 🚀
• Definition of severe CAP
• Diagnosis:
  • Pneumonia diagnosis
  • Differential diagnosis
• Post-diagnosis evaluation:
  • Laboratory studies
  • Imaging
  • Bronchoscopy
• Triage: who needs ICU?
• Treatment
  • Antibiotic selection
  • Resuscitation
  • Respiratory support
  • Steroid
  • Effusion management
• Treatment failure
• Duration of treatment
• Podcast
• Questions & discussion
• Pitfalls

---

rapid reference

(back to contents)

---

approach to severe CAP ✅

diagnostic evaluation

• History:
  • Travel?
  • Animal exposure?
  • Residence in TB-endemic country?
  • Recent healthcare contact? (admission, IV antibiotics?)
  • Review prior culture results (drug-resistant organisms?)
• Labs:
  • Blood cultures x2.
  • Sputum gram stain & culture if feasible (especially if intubated).
  • Nares PCR for MRSA.
  • Urine legionella & pneumococcal antigens.
  • Nasopharyngeal PCR: COVID, relevant viruses (e.g., influenza).
  • Procalcitonin and C-reactive protein (CRP).
  • Consider also:
    • HIV serology.
    • Sputum for fungus smear & culture.
• Imaging:
  • Review chest X-ray.
  • If imaging suggests effusion: POCUS.
  • Consider CT scan if:
    • Pneumonia diagnosis is uncertain (e.g., vs PE).
    • Substantial immunocompromise.
    • Unusual chest X-ray (e.g., cavities/nodules).

supportive care

• High-flow nasal cannula if significant dyspnea. 📖
• Consider steroid if no contraindication (e.g., 50 mg/day prednisone, or 40 mg/day methylprednisolone). 📖
• Avoid large-volume fluid resuscitation. 📖

atypical coverage

• Usually azithromycin 💉 500 mg IV daily x3 days. (Azithromycin is safe regardless of QTc and can be used in nearly all patients.)
• Animal exposure 🦜🐰🐑: Doxycycline 💉 100 PO/IV BID instead of azithromycin.

beta-lactam backbone

• Usually ceftriaxone 💉, 1-2 grams daily.
• Consider cefepime 💉 or piperacillin-tazobactam 💉 if risk for pseudomonas:
  • Structural lung disease (e.g. bronchiectasis, tracheostomy, or very severe COPD with frequent exacerbations).
  • Broad-spectrum antibiotics for >7 days within past month.
  • Hospitalization with IV antibiotics for >1 day within past three months.
  • Immunocompromise (e.g. chemotherapy, chronic use of >10 mg prednisone daily).
  • Nursing home resident with poor functional status.
  • History of pseudomonas infection or colonization.(34481570)

consider MRSA coverage

• Figure below indicates if MRSA coverage is required. If so:
  • Linezolid 💉 may be preferred (600 mg IV/PO q12 hours).
  • Vancomycin 💉 is also acceptable.

---

definition of severe community-acquired pneumonia

(back to contents)

---

definition of community acquired pneumonia (CAP)

• Community-acquired pneumonia refers to a pneumonia which begins when the patient is outside the hospital, or within the first <48 hours of hospital admission.
• “Healthcare-associated pneumonia” is no longer considered a valid diagnostic entity (based on evidence that this categorization fails to accurately identify patients harboring drug-resistant organisms). Such patients are now considered to have community-acquired pneumonia.

definition of severe community acquired pneumonia

• Severe community-acquired pneumonia is generally defined as patients admitted to the ICU due to community-acquired pneumonia.(35190510)

---

pneumonia diagnosis

(back to contents)

---

diagnosis is generally based on three lines of evidence:

• (1) Imaging evidence of a chest infiltrate (e.g., CXR, CT, ultrasound).
• (2) Systemic inflammation:
  • Symptoms: Night sweats, rigors, fevers.
  • Signs: Fever or hypothermia.
  • Labs: Leukocytosis, left-shift, elevated C-reactive protein, elevated procalcitonin.
• (3) Localizing signs and symptoms:
  • Symptoms: Dyspnea, cough, sputum production, pleuritic chest pain.
  • Signs: Hypoxemia, tachypnea, abnormal lung ascultation.

atypical presentations

• Elderly patients may present with non-pulmonary complaints (e.g., falling, delirium, sepsis).
• When in doubt, it is reasonable to get cultures and start antibiotics for pneumonia. Within the next 24-48 hours, the diagnosis may be re-considered and antibiotics discontinued as appropriate.

CT scan to assist the diagnosis of pneumonia

• Some patients with pneumonia will have a negative chest X-ray with a positive CT scan. Causes of reduced sensitivity of chest X-ray include:(Murray 2022)
  • Underlying structural lung disease (e.g., emphysema, bullae).
  • Severe obesity.
  • Neutropenia.
  • Very early in the disease course.
• CT scan can be especially helpful to detect pneumonia in patients with chronic lung disease and chronically abnormal chest X-ray (especially if a prior CT scan is available for comparison).
• Evidence supports the use of CT scan for pneumonia diagnosis:
  • One series found that a third of patients with suspected pneumonia and a negative chest X-ray had infiltrates detected by CT scan. These CXR-negative, CT-positive patients had outcomes similar to patients with infiltrates on chest X-ray, substantiating that these are “real” pneumonias detected on CT scan.(26168322)
  • Among 188 patients with infiltrates detected on chest X-ray, pneumonia was excluded by chest CT scan in nearly a third of patients. Prompt exclusion of pneumonia facilitates antibiotic stewardship and (more importantly) redirection of attention to the actual cause of the patient's illness.(26168322)
• 💡 Among patients who are older and unlikely to harmed by radiation, there should probably be a reduced threshold to obtain CT scan to facilitate prompt diagnosis and accurate therapy.

bronchoscopy – discussed further below 📖

---

differential diagnosis

(back to contents)

---

Below are some common considerations:

pulmonary embolism

• Clues:
  • Wedge-shaped pulmonary infarcts may masquerade as PNA.
  • Pulmonary infiltrates may be unimpressive compared to symptoms.
  • Right ventricular strain pattern on EKG/Echo.
  • Signs/symptoms of DVT (leg swelling, pain).
• Diagnostic tests: CT angiography.

PJP (Pneumocystis jiroveci pneumonia)

• Clues:
  • HIV (if the diagnosis is known).
  • Non-HIV: Chronic steroid use (>15 mg prednisone for >3 weeks), chemotherapy/immunosuppressive drugs.
  • Diffuse interstitial infiltrates.
• Diagnostic tests:
  • HIV serology is crucial to diagnosis of HIV-PJP.
  • Bronchoscopy with BAL sent for fungal stain & PCR.

endemic fungal pneumonia or cryptococcus

• Clues:
  • Often more indolent than bacterial pneumonia.
  • Radiologic pattern often nodular.
  • Can affect normal hosts (blastomycosis), but often affects immunocompromised patients (esp: TNF-inhibitors & steroid).
  • Exposure to endemic locations, bird/bat droppings (histoplasmosis), soil exposure (blastomycosis, coccidiomycosis).
• Diagnostic tests:
  • Urine antigens (e.g., blastomycosis, cryptococcus).
  • CT scan can be suggestive.
  • Bronchoscopy.

invasive aspergillosis

• Clues:
  • Neutropenia (especially >10 days)
  • High-dose steroid (e.g., pulse therapy for vasculitis)
• Diagnostic tests:
  • CT scan may help risk stratify.
  • Beta-D-Glucan, galactomannan.
  • Bronchoscopy.

septic pulmonary emboli

• Clues:
  • Diffuse infiltrates which tend to cavitate.
  • Often bacteremic with staph aureus.
  • Often seen in patients with intravenous drug use.
• Diagnostic tests:
  • CT scan shows characteristic pattern with multi-focal cavitation.
  • Echocardiogram shows tricuspid vegetation.

DAH (diffuse alveolar hemorrhage)

• Clues:
  • Hemoptysis (only 50% of patients however).
  • Diffuse infiltrates.
  • Renal failure or active urinary sediment (hematuria).
  • Falling hemoglobin.
  • May have previously diagnosed rheumatologic disease.
• Diagnostic tests:
  • Urinalysis: hematuria.
  • Markedly elevated ESR & CRP.
  • Bronchoscopy shows alveolar hemorrhage.
  • Serologies can be helpful (e.g. ANCA).

AEP (acute eosinophilic pneumonia)

• Clues:
  • Blood eosinophils over ~300/uL (unusual for severe pneumonia).
  • Younger adults with severe PNA, often requiring intubation.
  • Sometimes inhalational exposure (esp. recent-onset smoking).
• Diagnostic tests:
  • Bronchoscopy shows alveolar eosinophilia.

COP (cryptogenic organizing pneumonia)

• Clues:
  • Often more gradual onset than usual PNA.
  • Refractory to antibiotics.
• Diagnostic tests:
  • Hard to diagnose (tissue biopsy needed).

drug- or radiation-induced pneumonitis

• Clues:
  • Exposure to drug implicated in causing pneumonitis.
  • Most often: amiodarone, chemotherapeutics.
• Diagnostic tests:
  • Hard to diagnose.
  • Often diagnosis of exclusion, treated empirically.
  • Radiation pneumonitis may have a focal, non-anatomic distribution corresponding to the radiation field.

flare of interstitial lung disease

• Clues:
  • History of chronic pulmonary limitation.
  • Prior diagnosis of interstitial lung disease (often idiopathic pulmonary fibrosis).
• Diagnostic tests:
  • CT scan may be suggestive (honeycomb scarring).
  • Diagnosis of exclusion.

exacerbation of COPD

• Clues:
  • COPD exacerbation may clinically mimic pneumonia including hypoxemia, fever, and sputum production. This can be nearly impossible to sort out based on history and physical examination.
• Diagnostic tests:
  • Isolated COPD exacerbation should lack infiltrates on chest imaging and have a relatively low procalcitonin level.
  • Note that COPD exacerbation can coexist with bacterial pneumonia (“pneumonic COPD exacerbation”) – in which case both processes should be treated simultaneously.

atelectasis (+/- non-pulmonary infection)

• Clues:
  • Chest X-ray isn't impressive.
  • Clinical illness severity is disproportionate to the X-ray abnormalities.
  • Lack of prominent pulmonary symptoms.
• Diagnostic tests:
  • CT chest may be helpful to exclude severe pneumonia.
  • Best strategy is to look for and find an alternative diagnosis.
• 💡 A common error is to assume that the septic shock must be due to pneumonia, when in fact the chest infiltrates are a red herring. When in doubt, err on the side of investigating further to exclude an alternative source of sepsis.

aspiration pneumonitis

• Clues:
  • History of aspiration or swallowing problems.
  • Repeated episodes of pneumonia with rapid recovery.
  • Infiltrates located in dependent lung segments.
• Diagnostic tests:
  • May be impossible to diagnose up-front.
  • CXR clears very rapidly (over 24-48 hours).
  • Procalcitonin is often negative.

---

labs to obtain after diagnosing pneumonia

(back to contents)

---

blood cultures

• Recommended for severe pneumonia, although yield is low (~10%).(29968985)
• ⚠️ If patient already had blood cultures at another hospital, don't repeat them (follow up on results from the outside hospital lab).

sputum for gram stain & culture for bacteria

• Overall utility:
  • Intubated patient: tracheal aspirate is very useful.
  • Non-intubated patient: expectorated sputum is only occasionally useful, yet still recommended.(29968985) Many patients are incapable of producing sputum.
• Quality:
  • A high-quality sputum sample should have >25 leukocytes and <10 squamous cells per low-power field.(Murray 2022) >10 squamous epithelial cells per low-power field indicates excessive oropharyngeal contamination, so the specimen should be discarded.
  • If a good-quality sputum culture reveals a single dominant morphology of bacteria on gram stain, that is strong evidence regarding the etiology of pneumonia.
  • If numerous different morphologies of bacteria are seen in similar amounts, then the sputum gram stain is often meaningless (reflective of normal flora).
• Sensitivity of sputum culture for different organisms:
  • Streptococcus pneumoniae or Haemophilus influenzae are fastidious organisms that are difficult to grow. Consequently, sputum culture is often negative.
  • Staphylococcus aureus and gram-negatives tend to grow exuberantly, even if they merely represent colonization. If sputum culture is positive for Staphylococcus aureus or a gram-negative organism but this isn't seen in a high-quality sputum sample, it's dubious whether the sputum culture truly reflects pneumonia.(Murray 2022)

sputum for fungus culture & smear

• Fungal smear typically involves a combination of potassium hydroxide and Calcofluor white. Potassium hydroxide dissolves human tissue (but not fungi), removing debris from the slide.
• Fungal culture and smear should be ordered if imaging or epidemiological data suggests the possibility of a fungal pneumonia (e.g., blastomycosis, histoplasmosis, cryptococcus neoformans, coccidiomycosis).

urine legionella antigen

• Sensitivity ~75% and specificity of ~95%.(29968985)
• A negative result doesn't exclude legionella.
• A positive result is important, since patients with legionella may benefit from extended courses of antibiotic (e.g., azithromycin 500 mg IV daily for 7-10 days, instead of three days).

urine pneumococcal antigen

• Sensitivity ~75% and specificity 95%.
• False-positive may occur due to pneumonia within the past several weeks, or recent pneumococcal vaccination.(29968985, 29119848)

nares PCR for MRSA

• MRSA nares PCR can be reliably used to guide empiric and targeted antibiotic therapy, with a negative predictive value of 96-99%.(32127438, 32101906)

nasopharyngeal PCR for COVID and viruses (e.g. influenza).

• If nasopharyngeal influenza PCR is negative and high suspicion remains, a lower respiratory tract PCR may be positive.(21048054)
• Be careful: patients may be co-infected with viral and bacterial pathogens. Just because the viral PCR is positive doesn't mean that you should stop antibacterial therapy.(29968985)

procalcitonin

• Procalcitonin is not intended to guide the initiation of antibiotics. However, procalcitonin may support the clinical judgement to discontinue antibiotics (thereby functioning as an antibiotic-stopping tool).
• Procalcitonin <0.25 ng/mL argues against typical bacterial pneumonia.
  • ⚠️ However, procalcitonin is often not elevated among patients with atypical infections.(32127438) For patients with a negative procalcitonin it may be reasonable to discontinue beta-lactam antibiotics, but continue coverage for atypical pathogens (with azithromycin or doxycycline).
• Procalcitonin is unreliable in immunocompromised patients (e.g. neutropenia).
• More on procalcitonin: 📖

C-reactive protein (CRP)

• CRP may be useful, especially in situations where procalcitonin is unavailable or has a long turn-around time.
• CRP <<50 mg/L (<<5 mg/dL) should prompt reconsideration of whether the patient actually has pneumonia.(26472401)
• CRP >150 mg/L (>15 mg/dL) indicates a high inflammatory response, which might imply greater utility of steroid. (25688779)
• CRP >250 mg/L (>25 mg/dL) may raise suspicion for Legionella pneumonia.(12762360)
• If CRP is markedly elevated and procalcitonin is normal, this suggests an inflammatory pneumonitis which isn't caused by typical bacterial pathogens (e.g., viral pneumonia, acute eosinophilic pneumonia, diffuse alveolar hemorrhage).

HIV screening test

• Consider for any patient who is at potential risk.
• Yield is low, but when positive this has enormous implications for patient management.

---

imaging considerations after pneumonia diagnosis

(back to contents)

---

imaging modality

• Chest X-ray:
  • Useful for all patients.
  • Global study may be useful to track progress over time.
• Chest CT scan may be indicated for more advanced evaluation, for example in patients with:
  • Immunocompromise.
  • Unusual chest imaging (e.g. chest X-ray suggestive of nodular/cavitating pneumonia).
• Ultrasonography for effusion:
  • If there is any doubt regarding possible effusion (e.g. basilar opacities), bedside ultrasonography should be performed to clarify this.
  • Ultrasonography should be repeated every 1-2 days to surveil for the development of an effusion or empyema over time.

---

radiographic patterns of pneumonia

---

Radiographic patterns of pneumonia cannot entirely be relied upon. However, they can provide useful diagnostic clues, so they shouldn't be ignored either.

lobar consolidation

• Radiographic features:
  • Single or multiple areas of dense consolidation (not necessarily involving an entire lobe, despite the name “lobar pneumonia”).
  • Air bronchograms may be seen. When present, these argue against a central bronchial obstruction as causing the pneumonia.(Shepard 2019)
  • Areas outside of consolidated regions are spared.
  • Bulging fissure sign may result from expansion of the affected lobe. This is classically associated with Klebsiella, but can occur with any lobar pneumonia.(Shepard 2019)
  • Round pneumonia is a term referring to a single focus of consolidative pneumonia with a round contour. This is a subset of lobar pneumonia, with similar treatment implications. However, additional diagnostic considerations might include Coxiella burnetii, fungi, or early septic emboli.(Shepard 2019)
• Clinical features:
  • Pleural extension often causes pleuritic chest pain.
• Commonly implicated organisms:
  • Streptococcus pneumoniae.
  • Haemophilus influenzae.
  • Klebsiella pneumoniae.
  • Legionella.

bronchopneumonia

• Radiographic features:
  • Chest X-ray may show patchy, diffuse opacities.
  • Multiple, ill-defined centrilobular nodular opacities may range from 5-10 mm, in some cases appearing to have a tree-in-bud pattern.
  • Small-moderate sized areas of consolidation may occur. In severe cases, consolidated areas may progress to the point of confluence (which may become indistinguishable from a lobar pneumonia).(Shepard 2019)
• Commonly implicated organisms:
  • Staphylococcus aureus.
  • Pseudomonas and other gram negative organisms.
  • Nonencapsulated Haemophilus influenzae.
  • Mycoplasma, chlamydiae.

interstitial pneumonia

• Radiographic features:
  • Diffuse ground glass opacities.
  • Septal thickening.
• Causes:
  • Mycoplasma, chlamydia.
  • Viral pneumonia (e.g., influenza).
  • Pneumocystis jiroveci (PJP).
  • Noninfectious mimics: heart failure, lymphangitic carcinomatosis, drug-induced pneumonitis.

cavitation

• If mostly infiltrate, with some cavitation:
  • Staphylococcus aureus (especially MRSA).
  • Streptococcus groups A-D.
  • Gram negatives (e.g., Pseudomonas, Klebsiella, Proteus, Serratia).
  • Legionella.
• If multiple, prominent bilateral cavities:
  • Septic pulmonary emboli.
  • Nocardia.
  • Fungal pneumonia.
  • Tuberculosis.
• If unilateral, with cavity larger than infiltrate: consider anaerobic lung abscess.

nodular pattern

• Fungal pneumonia, nocardia, mycobacterial (all of these usually indolent).
• Septic pulmonary emboli (prior to cavitation).
• Non-infectious (e.g. malignancy, granulomatosis with polyangiitis).

pleural effusion

• Not very specific. Most commonly associated with pneumococcus, haemophilus influenzae, group A streptococcus, legionella.

pneumothorax

• Septic pulmonary emboli may cause cavitation and then pneumothorax.
  Pneumocystis jiroveci.

chest wall involvement

• Actinomycosis species.
• Nocardia.
• Granulomatous organisms including tuberculosis.

---

bronchoscopy

(back to contents)

---

Bronchoscopy is only rarely useful in the management of community-acquired pneumonia.

bronchoscopy for the diagnosis of bacterial community-acquired pneumonia

• Bronchoscopy is occasionally useful to exclude a non-infectious pneumonia mimic (e.g. diffuse alveolar hemorrhage, eosinophilic pneumonia).
• Bronchoscopy may be useful to exclude an unusual infection, primarily:
  • Fungal pneumonia.
  • Pneumocystis jirovecii pneumonia.
• The indications for bronchoscopy are predominantly indicators that patients may have a non-bacterial process, for example:
  • CT scan shows cavitation, nodules, and/or diffuse ground glass opacification.
  • The patient is profoundly immunocompromised, increasing the risk of unusual organisms.

performance of bronchoscopy for bacterial pathogens

• Bronchoalveolar lavage (BAL) is subject to contamination with oropharyngeal flora, so culturing an organism doesn't necessarily indicate that it represents an invasive pneumonia.  (This may be reduced by the use of protected brush cultures.)
• When bronchoscopy is used to obtain different specimens, there is a 20-40% rate of disagreement between the different specimens!
• Overall, the sensitivity and specificity of bronchoscopy for bacterial culture is unimpressive.

---

triage: who needs ICU?

(back to contents)

---

No criteria apply perfectly for every patient. However, the IDSA/ATS criteria may provide a useful conceptual framework for borderline situations.

classic errors in pneumonia triage

• (1) Triage solely based on the amount of oxygen the patient requires:
  • A common myth is that if the patient can saturate adequately on nasal cannula then it's OK for them to go to the ward. This is completely and utterly wrong.
• (2) Triage based on CURB65 and PORT scores:
  • These are validated as mortality prediction tools, they aren't designed to determine disposition.
  • These are not great at sorting out who needs the ward vs. ICU.

IDSA/ATS criteria for severe pneumonia

• These criteria have been validated for use in ICU triage (with severe pneumonia patients meriting ICU admission). Severe pneumonia is defined by either having at least one major criteria, or at least three minor criteria.(29609223, 21865188, 19789456)
• Major criteria (only 1 required):
  • Respiratory distress requiring mechanical ventilation. These criteria were created prior to the common use of high-flow nasal cannula. A patient with substantial work of breathing or tachypnea (e.g., respiratory rate >30) who requires high-flow nasal cannula should be considered for ICU admission.(29119848, 18513176)
  • Septic shock.
• Minor criteria (at least 3 required):
  • Respiratory rate >29 breaths/min.
  • Hypotension requiring volume resuscitation.
  • PaO2/FiO2 <250 (very roughly may correspond to requiring >3 liters oxygen).(17573487)
  • Temperature <36C.
  • Confusion.
  • Multi-lobar infiltrates.
  • BUN >20 mg/dL (>7 mM).
  • WBC <4,000/mm3.
  • Platelets <100,000/mm3.

---

antibiotic selection

(back to contents)

---

don't forget atypical coverage!

• Atypical coverage should always be included in the empiric antibiotic regimen for severe pneumonia.
  • Legionella causes ~10-15% of severe pneumonia. This won't be covered by the broadest beta-lactams in the world (e.g. cefepime, piperacillin-tazobactam, meropenem).
• Azithromycin 💉 is an excellent choice here:
  • Solid track record in pneumonia.
  • Retrospective studies suggest mortality benefit, even in pneumococcal pneumonia sensitive to beta-lactams (possibly due to anti-inflammatory activity, or coinfection with atypical pathogens).
  • If the patient is diagnosed with pneumococcus, azithromycin should still be continued for 3-5 days.(17452932, 30118377)
  • Azithromycin is well-tolerated and very safe. Don't worry about the QT interval, the concept that azithromycin causes torsade de pointes is mythological.(24893087)
• Doxycycline 💉 is also an excellent choice for atypical coverage, with the following advantages:
  • Doxycycline covers most organisms acquired from animal contact:
    • Coxiella burnetii (Q-fever) – usually seen in farmers or veterinarians due to contact with cattle, sheep, goats, cats, dogs, or rabbits.
    • Tularemia – acquired from rabbits
    • Leptospirosis – acquired from animal urine.
    • Psittacosis – acquired from birds.
  • Doxycycline is generally active against MRSA in vitro, but it's unclear whether this is effective for clinical MRSA pneumonia.
• Fluoroquinolones are a poor choice for atypical coverage in the ICU for several reasons. 🌊

beta-lactam backbone

• The beta-lactam backbone will cover gram-positives (especially pneumococcus) and gram negatives.
• Ceftriaxone 💉 is an excellent choice for most patients.
  • It's controversial whether to use 1 or 2 grams IV daily. Increasing drug resistance over time may be an argument to use 2 grams. This should also be considered in obese patients.
  • Ceftriaxone is safe to use in most patients with penicillin allergy. 📖
• Antipseudomonal beta-lactam (piperacillin-tazobactam 💉 or cefepime 💉) may be considered in patients with risk factors for pseudomonas, for example:
  • Structural lung disease (e.g. bronchiectasis, tracheostomy, or very severe COPD with frequent exacerbations).
  • Broad-spectrum antibiotics for >7 days within past month.
  • Hospitalization with IV antibiotics for >1 day within past three months.
  • Immunocompromise (e.g. chemotherapy, chronic use of >10 mg prednisone daily).
  • Nursing home resident with poor functional status.
  • History of pseudomonas infection or colonization.(34481570)
• Patients with penicillin allergy can generally receive these antibiotics without an issue (discussed further here: 📖).

MRSA coverage is occasionally needed as 3rd drug

• MRSA is an uncommon cause of community-acquired pneumonia, with rates of ~1-3%.(32101906, 32805298) This varies depending on geography and patient population, but overall most patients with community acquired pneumonia do not need MRSA coverage.
• Risk factors for MRSA are different from risk factors for drug-resistant gram negative organisms. Thus, a one-size-fits-all approach towards all drug-resistant organisms is suboptimal. A tailored strategy to guide the use of MRSA coverage is shown above.(more detail here)
• Regardless of the exact approach used, the key is ongoing and thoughtful evaluation of data.
  • Staph generates lots of purulent sputum and is generally not difficult to isolate.
  • MRSA PCR has an excellent negative predictive value, so a negative PCR can often allow for discontinuation of MRSA coverage.(32127438, 32101906)
  • MRSA coverage should be stopped within <48-72 hours unless there is some objective data that the patient has MRSA.
  • Cavitary pneumonia raises the possibility of Panton-Valentine leukocidin (PVL) toxin-producing strains of MRSA. These strains are often community-acquired and extremely aggressive, causing necrotizing pneumonia among otherwise healthy individuals. Optimal therapy might include toxin-suppressive antibiotics (e.g., linezolid +/- rifampicin).(35190510)
• Choice of agent:
  • Linezolid 💉 is arguably first-line therapy for MRSA pneumonia (compared to vancomycin, linezolid has superior lung penetration, causes no nephrotoxicity, and suppresses bacterial toxin synthesis).(26859379, 22247123)
  • Vancomycin 💉 is the traditional option if linezolid is contraindicated. Unfortunately, resistance to vancomycin is increasing over time. If susceptibility testing shows borderline sensitivity to vancomycin (MIC 1.5-2 mcg/mL) this may increase the risk of treatment failure and an alternative agent might be better. If the MIC is >2 mcg/mL then a different antibiotic should definitely be used.
  • Ceftaroline 💉 is a fifth-generation cephalosporin active against MRSA. It might be superior to vancomycin (particularly for strains with MIC>1 mcg/mL), but there is no high-quality evidence available.(28702467, 29147471)
  • (Daptomycin isn't an option here because it is degraded by surfactant and thus cannot treat pneumonia.)

double-coverage for pseudomonas is not needed

• Unless you're living in a post-apocalyptic hellscape where pseudomonas are insanely resistant to beta-lactams, this shouldn't be necessary. Double-coverage doesn't even appear to benefit patients with ventilator-associated pneumonia (which involves a much greater risk of resistant pseudomonas). More on this here.

anaerobic coverage is not needed for pneumonia

• Sometimes there is concern that the patient may have aspirated, so they should be covered for anaerobes.
• The lung is the best oxygenated organ in the body, so it is not very susceptible to anaerobic infection. The only way anaerobic infection can occur is if there is an anatomic disruption that creates a poorly oxygenated compartment (abscess or fluid collection).
  • 💡 Anaerobic coverage is indicated only for empyema or lung abscess.

---

resuscitation

(back to contents)

---

avoid large-volume fluid resuscitation

• Large volume fluid resuscitation may worsen hypoxemic respiratory failure and thereby precipitate the need for intubation.
• Most patients with pneumonia can be stabilized adequately with small-moderate volumes of fluid combined with vasopressors if needed.
  • Consider early institution of vasopressors. In many cases, a low-dose vasopressor (e.g. norepinephrine 5-10 mcg/min) may substantially reduce the amount of fluid which is needed to stabilize the patient.
• Fluid should be used only if the following conditions are met:
  • Organ hypoperfusion (e.g. poor urine output) or refractory hypotension PLUS
  • History and evaluation indicates true volume depletion (as opposed to hypotension which is merely due to vasodilation). Please note that a reduced central venous pressure or collapsed inferior vena cava doesn't necessarily indicate volume depletion, these findings can also be caused by systemic vasodilation.
• Lactate elevation is not a sign of organ malperfusion, nor is it an indication for fluid.

---

respiratory support

(back to contents)

---

high-flow nasal cannula (HFNC)

• The FLORALI trial suggested improved mortality among patients with severe hypoxemia treated with HFNC.
• HFNC should be considered in patients with significant work of breathing and/or tachypnea. The goal of HFNC is to reduce the work of breathing, and thereby prevent patients from tiring out. In order for this to work, HFNC must be started before the patient is exhausted and in extremis.
• Advantages of HFNC:
  • Oxygenation support
  • Ventilation support due to dead-space washout
  • Humidification may promote secretion clearance
  • Doesn't interfere with sputum clearance, coughing, or eating
  • Patients may remain on HFNC for several days if needed (often the case for severe lobar pneumonia).

typically avoid BiPAP

• BiPAP doesn't allow patients to clear their secretions. Patients treated on BiPAP often do well initially, but eventually may fail due to retained secretions and mucus plugging.
• BiPAP may be used for limited periods of time to stabilize patients (e.g. for transportation).
• Occasional patients with COPD plus pneumonia may benefit from a rotating schedule of BiPAP and HFNC. Pulmonary toilet and secretion clearance may be performed while the patient is on HFNC.

endotracheal intubation

• This is usually used as a second-line therapy, after trying HFNC.
• Indications for intubation in pneumonia are usually:
  • Refractory hypoxemia
  • Progressively worsening work of breathing, respiratory exhaustion

---

steroid

(back to contents)

---

• Several RCTs and meta-analyses have shown that steroid may reduce the length of stay and risk of intubation among pneumonia patients. The SCCM/ESICM guidelines currently recommend steroid for patients with severe community-acquired pneumonia.(29090327)
• Steroid should be considered for patients with severe pneumonia in the absence of contraindications.
• Patients in whom steroid may be contraindicated:
  • Paralytic infusion (risk of myopathy).
  • Suspicion of pneumonia due to fungus, tuberculosis, or possibly influenza.
  • Immunocompromise (HIV, chemotherapy, neutropenia).
  • History of steroid-induced psychosis.
• There is no specific regimen of steroid. The following are all reasonable options:
  • Prednisone burst (e.g., 50 mg PO daily for 5 days) or equivalent dose of methylprednisolone (40 mg/day IV).
  • Dexamethasone 12 mg once, then 6 mg/day for 4 days.
  • Traditional stress dose steroid (50 mg hydrocortisone IV q6hr) – this may be preferred for patients in shock.

---

effusion management

(back to contents)

---

pleural effusion management

• Pleural effusion and empyema are common in severe pneumonia.
• Effusion should be evaluated upon admission and every 1-2 days thereafter, using bedside ultrasonography.

management is driven by ultrasonographic features:

• Effusion is small & anechoic (black, without internal echoes) ==> follow with daily ultrasonography, intervene if the effusion expands.
• Effusion is large & anechoic ==> drain effusion dry with thoracentesis.
• Effusion contains septations ==> place pigtail catheter, add tPA/DNAse if complete drainage doesn't occur.

---

treatment failure

(back to contents)

---

defining treatment failure

• There is no clear definition, but clinical improvement should generally be seen within ~3 days among immunocompetent patients. (34481570)
• Persistent or rising procalcitonin or CRP over several days may be an early sign of treatment failure. (Note, however, that procalcitonin will often rise over the first day or so, even among patients who improve clinically).
• Ongoing deterioration in oxygenation and infiltrates >24 hours after antibiotics is the most concerning feature.
• Radiographic improvement takes weeks, so failure for chest x-ray to improve over a few days is expected. Indeed, if the chest x-ray clears up within 24-48 hours that might be suggestive of aspiration pneumonitis, rather than true bacterial pneumonia.

differential diagnosis

• Incorrect initial diagnosis, e.g.: 📖
  • Heart failure.
  • Pulmonary embolism.
  • Diffuse alveolar hemorrhage.
  • Cryptogenic organizing pneumonia.
  • Eosinophilic pneumonia.
  • Bronchoalveolar carcinoma.
  • Interstitial lung disease.
• Antibiotic problem:
  • Wrong antibiotic, e.g.:
    • Multidrug resistant organism.
    • Endemic fungal pneumonia or cryptococcus.
    • Invasive aspergillosis.
    • PJP (pneumocystis jirovecii pneumonia).
    • Tuberculosis.
    • Q-fever or tularemia (may resist azithromycin).
  • Inadequate antibiotic dose or penetration into lung tissue.
• Intrathoracic complication:
  • Lung abscess or necrotizing pneumonia.
  • Pleural effusion, e.g.:
    • Empyema.
    • Large parapneumonic effusion causing respiratory dysfunction.
  • Fibroproliferative ARDS.
  • Cryptogenic organizing pneumonia (COP).
  • Pulmonary superinfection, e.g.:
    • Ventilator-associated pneumonia.
    • Invasive aspergillus infection in the context of influenza or COVID-19.
• Extrathoracic infection:
  • Metastatic infection:
    • Endocarditis.
    • Meningitis.
    • Septic arthritis.
  • Line infection (secondary to bacteremia from the pneumonia, or unrelated to the pneumonia).
  • C. difficile colitis.
• Noninfectious complication of hospitalization:
  • Iatrogenic volume overload.
  • Pulmonary embolism.
  • Drug fever.
  • Aspiration pneumonitis.
  • Atelectasis.
  • Cardiovascular complication (e.g., atrial fibrillation, myocardial infarction).
• Correct diagnosis and appropriate treatment, with slow resolution:
  • Certain pathogens may respond slowly even if treated correctly (e.g., legionella, gram-negative bacteria, Staph. aureus).(35190510)
  • Weak host.

approach

• Review all data carefully (especially microbiology).
• CT angiogram of the chest is generally performed to secure the diagnosis of pneumonia and exclude pulmonary embolism or anatomic complication (e.g., abscess or empyema).
• Repeat cultures (blood and sputum).
• HIV screen if not previously performed.
• Bronchoscopy may be considered.
• If a significant pleural effusion is present, it may be drained and sampled.
• Procalcitonin and/or CRP may help sort out infectious vs. noninfectious illness:
  • Negative procalcitonin (<0.25 ng/ml) after three days suggests the presence of a non-infectious complication, whereas persistently elevated procalcitonin suggests active infection.
  • Among patients with renal insufficiency, C-reactive protein might be used in an analogous fashion (with CRP levels <30 mg/L roughly analogous to a negative procalcitonin).(19762338)

---

duration of treatment

(back to contents)

---

Either time or procalcitonin may be used to guide the length of treatment. When in doubt, both factors may be considered:

time-based strategy:

• 5-7 days of treatment is generally adequate
• Indications for longer treatment:
  • Bacteremic infection with Staphylococcus aureus or Pseudomonas.
  • Legionella pneumonia.
  • Metastatic infection involving other organs (e.g., meningitis).
  • Anatomic complication (e.g. necrotizing pneumonia, lung abscess).

procalcitonin-based strategy:

• The following suggest discontinuation of antibiotic:
  • Procalcitonin level <0.25 ng/ml.
  • Procalcitonin has fallen to <20% the peak value.
• May be useful to support antibiotic discontinuation in a patient who remains clinically ill for non-infectious reasons (e.g. COPD exacerbation, ARDS).
• Not applicable in following situations:
  • Immunocompromise.
  • Renal dysfunction (PCT may have sluggish kinetics).
  • Patient has other causes of elevated procalcitonin (e.g. other site of infection, burns, trauma, surgery, pancreatitis).

---

podcast

(back to contents)

---

Follow us on iTunes

---

questions & discussion

(back to contents)

---

To keep this page small and fast, questions & discussion about this post can be found on another page here.

• Failure to cover for atypical (e.g. treating with piperacillin-tazobactam monotherapy).
• Unnecessary MRSA coverage in patients at low risk for MRSA. In particular, after 48 hours if there is no evidence that the patient has MRSA (e.g. negative nares PCR & negative sputum), then MRSA coverage should be stopped.
• Triaging patients based on their oxygen requirement, while ignoring tachypnea and work of breathing.
• Under-utilization of steroid (especially in patients who may benefit substantially, e.g. underlying asthma/COPD).
• Missing a pleural effusion which develops insidiously after admission.
• Egregiously weird antibiotic regimens for patients with dubious penicillin allergy. 📖
• Using fluoroquinolones (it's a trap).
• Giving clindamycin for anaerobic coverage.
• Double-coverage of pseudomonas.
• Dumping 30 cc/kg fluid into a sick pneumonia patient on the verge of intubation because the lactate is elevated.

Guide to emoji hyperlinks

• = Link to online calculator.
• = Link to Medscape monograph about a drug.
• = Link to IBCC section about a drug.
• = Link to IBCC section covering that topic.
• = Link to FOAMed site with related information.
• = Link to supplemental media.